Sasha Schrode is the CEO of FEMSelect and a member of the company’s board of directors. Sasha brings over 20 years of experience in healthcare where she has focused on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency. Prior to joining FEMSelect, she founded Serpex Medical, a MedTech company that was acquired in 2023. Under her leadership, she has brought transformational MedTech innovations to market while creating value to shareholders.
Sasha is also a Partner at Robin Hood Ventures and serves on the board of FEMSelect, The American Lung Association, Cooler Heads, University of Penn’s Health Technology and is an advisor to FloBio and RTM Vital Signs. She has a B.A in Business Administration and a M.B.A in Finance and Healthcare Administration. Sasha is passionate about advancing women’s health and leveraging her expertise to deliver impactful solutions worldwide.
